Dr. Mihai Turcu
Mihai is a rheumatology resident at the Emergency Clinical County Hospital of Craiova, Romania, and a PhD candidate with a research focus on adipose tissue dysfunction and immunometabolic phenotypes in rheumatic diseases. His broader clinical and research interests span systemic autoimmune diseases, health economics, outcomes research, and the application of artificial intelligence in healthcare. He has co-authored several peer-reviewed publications investigating healthcare-related outcomes, quality of life, and disease burden in patients with rheumatic diseases.
| Poster 0124| Sunday, 08.11.26 10:30 Poster Session A: Innate Immunity Poster Presenting author: J. Lee (South Korea) Title: Spatial and Transcriptomic Characterization of the Gouty Tophus as a Structured Inflammatory Microenvironment: Evidence for SPP1 ⁺ Macrophage-Fibroblast Crosstalk and Local Complement Activation  This spatial transcriptomics study reveals that the gouty tophus is a highly organized inflammatory microenvironment driven by dynamic crosstalk between SPP1⁺ macrophages and tissue fibroblasts, offering novel cellular targets beyond traditional urate-lowering strategies. |
| Poster 0712| Sunday, 08.11.26 10:30 Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster Presenting author: R. Kasiraj (USA) Title: Gout Flare Burden and Cardiorenal Outcomes With Glucagon-Like Peptide-1 Receptor Agonists Versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus and Gout: A Propensity-Matched Retrospective Study This propensity-matched cohort study found an association between GLP-1 receptor agonist use and lower gout flare rates and better cardiorenal outcomes compared to DPP-4 inhibitors in patients with co-existing diabetes and gout. |
| Poster 0715| Sunday, 26.10.25 10:30 Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster Presenting author: C. Diaz-Torne (Spain) Title: Isolated, Metabolic, and Hypertensive Gout: A Population-Based Cluster Analysis of 94,759 Patients By applying population-based cluster analysis to nearly 95,000 patients, this study categorizes gout into three distinct clinical phenotypes, paving the way for personalized therapeutic strategies based on metabolic and cardiovascular risk profiles |
| Poster 1654| Monday, 09.11.26 10:30 Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster Presenting author: L. Suarez-Zorrilla (Spain) Title: Prevalence and Factors Associated with Crowned Dens and Crowned Dens Syndrome in Patients with Calcium Pyrophosphate Arthritis This retrospective CPP crystal arthritis study reviewed CT scans in 173 of 328 patients. Crowned dens was detected in 102/173 (59.0%), and crowned dens syndrome in 27/173 (15.6%). Age and longer disease duration were independently associated with crowned dens. The syndrome was associated with a chronic inflammatory phenotype. These findings support reviewing available CT scans, while the hospital-based, CT-selected sample limits generalisability. |
| Poster 2651| Tuesday, 10.11.26 10:30 Poster Session C: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster Presenting author:P. Khanna (USA) Title: Pooled Results From the Phase 3 Trials of Nanoencapsulated Sirolimus Plus Pegadricase in Uncontrolled Gout: Characterization of Adverse Events of Special Interest This pooled analysis of the phase 3 DISSOLVE trials assessed adverse events with nanoencapsulated sirolimus plus pegadricase in uncontrolled gout. Gout flare rates were similar with high-dose treatment, low-dose treatment and placebo (42.5%, 44.3% and 43.3%). Stomatitis occurred in 9.2%, 3.4% and 0%, respectively. Sirolimus-associated events were generally mild to moderate and did not lead to treatment discontinuation. The analysis characterises tolerability rather than demonstrating reduced infusion reactions. |
| Poster 2644 | Tuesday, 10.11.26 10:30 Poster Session C: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster Presenting author: P. Mandl (Austria) Title: Assessing the Reliability of the Ultrasound Semiquantitative Scoring System for Gout – a Patient-Based Reliability Study by the OMERACT Ultrasound Working Group This initial live-patient assessment by OMERACT showed overall moderate reliability for the proposed semiquantitative ultrasound scoring system in gout, highlighting the need for further studies to improve scoring accuracy and application. |